TSCA Reform: Senate Committee Holds Hearing on Frank R. Lautenberg Chemical Safety for the 21st Century Act

Bergeson & Campbell, P.C.

On March 18, 2015, the Senate Environment and Public Works Committee held a hearing on the Frank R. Lautenberg Chemical Safety for the 21st Century Act (S. 697). A detailed analysis of S. 697 is available in our March 13, 2015, memorandum. There were a number of references to the late Senator Frank R. Lautenberg (D-NJ), who introduced several bills intended to reform the Toxic Substances Control Act (TSCA), and whether the current bill would accomplish his goals. Throughout the hearing, there were many comments regarding allowing the perfect to be the enemy of the good. Supporters of S. 697 maintain that it significantly improves TSCA, providing more authority and funding to the U.S. Environmental Protection Agency (EPA) to regulate new and existing chemicals. Critics of the bill argue that while the perfect may be the enemy of the good, S. 697 is not a good bill.

Mrs. Bonnie Lautenberg, Senator Lautenberg's widow, spoke at the beginning of the hearing, describing Senator Lautenberg's work on TSCA reform. She stated that Senator Lautenberg wanted TSCA reform to be his final, enduring legacy, and that he understood that it required the art of compromise. According to Mrs. Lautenberg, Senator Lautenberg chose to work with Senator David Vitter (R-LA) to introduce the Chemical Safety Improvement Act (S. 1009) (CSIA), which was a compromise bill rather than a "winner take all" bill, and this compromise bill set the stage for S. 697. Mrs. Lautenberg noted that some are still waiting for a winner-take-all bill, but urged Congress not to let the interests of a few states undermine the interests of the rest of the country.

Senator Tom Udall (D-NM), who continued to work with Senator Vitter on revisions to the CSIA and in preparing S. 697, noted that an earlier bill from Senator Lautenberg, the Safe Chemical Act, which received no Republican support and had no Republican co-sponsors, failed to move out of Committee in 2011. Senator Udall described Senator Lautenberg's efforts, in his final days, to put his idea of perfection aside and find compromise. Senator Udall noted that New Mexico and many other states have very little protection from toxic chemicals, and with an estimated cost of $2.5 million to assess and regulate a chemical, lack the resources to do so on their own.

Witnesses at the hearing included:

  • Mr. Jim Jones, Assistant Administrator for the Office of Chemical Safety and Pollution Prevention, U.S. Environmental Protection Agency (EPA);
  • Mr. Ken Cook, President and Co-Founder, Environmental Working Group (EWG);
  • The Honorable Brian E. Frosh, Attorney General, State of Maryland;
  • Dr. Lynn Goldman, Dean, Milken Institute School of Public Health, The George Washington University;
  • Dr. Edward McCabe, Senior Vice President and Chief Medical Officer, March of Dimes Foundation; and
  • Dr. Richard Denison, Senior Scientist, Environmental Defense Fund (EDF).

In his testimony, Jones noted that there is no mandatory program under TSCA for the review of existing chemicals. The Obama Administration is committed to using its authority under TSCA to the fullest extent possible to regulate existing chemicals. Jones stated that the Obama Administration has not yet developed a formal position on S. 697, but continues to support EPA's September 2009 principles for reform of chemicals management legislation. Jones acknowledged that the principles do not address the issue of state preemption but that the Obama Administration will look hard at how state preemption is addressed in whatever bill Congress considers.

After Jones testified, Senators had a number of questions concerning issues such as:

  • The length of time it would take EPA to complete its review of the first 25 chemicals -- Jones cited statistics from his Office of Pesticide Programs (OPP) experience in implementing the Food Quality Protection Act (FQPA), showing it could handle about 40 actions/year and thought this likely the maximum on the chemicals side.
  • Whether S. 697 would allow industry to "buy" its way out of state regulation by paying EPA to conduct reviews -- Jones noted that the bill did not accord such reviews the same preemption treatment as for other EPA actions.
  • State co-enforcement and preemption -- Jones noted the bill would have some preemption effect and that these issues were handled differently under the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA).
  • Whether state regulations such as Proposition 65 would be prohibited -- Jones indicated that Proposition 65 was unaffected.
  • Whether cost-benefit is out of the safety assessment and determination -- Jones agreed it was.
  • Whether there is a deadline for industry to apply a given control action -- Jones agreed this was not included.
  • Whether the approaches in S. 697 meet all of EPA's principles -- Jones agreed that most were met, although there are technical issues regarding treatment of articles and there is not a timely requirement for control measures to enter into effect.
  • Whether the principles are EPA's only considerations -- Jones indicated that other issues were also being considered.
  • Are accidental spills covered by "conditions of use"? -- Jones agreed they are covered.
  • Does S. 697 allow EPA to share confidential business information (CBI) with states? -- Jones stated that it does.
  • Should low priority designations be subject to judicial review as final agency actions? -- Jones agreed these types of decisions are typically reviewable.
  • Does S. 697 protect CBI as well as TSCA? -- Jones indicated TSCA allowed too much information to be claimed as CBI and S. 697 requires substantiation and other steps that should limit such claims, and that S. 697 otherwise protects CBI as did TSCA.
  • Are the deadlines for EPA development of policies and procedures reasonable? -- Jones agreed EPA could meet the requirements with the fee provisions included.
  • Are vulnerable populations covered? -- According to Jones, yes.
  • Does EPA support use of cost-benefit analysis? -- Jones indicated that EPA does support cost-benefit analysis, although it is frequently difficult to monetize benefits.

In his questions to Jones, Senator Vitter emphasized that S. 697 would grandfather permanently all current state chemical regulations enacted as of January 1, 2015, including Proposition 65. Jones agreed with Senator Vitter's assessment that S. 697 would provide EPA the authority to reject any industry request to prioritize a chemical, and limit the number of chemicals prioritized at the request of industry. Senator Vitter also clarified when a chemical is prioritized this way, the preemption rules are different.

The second panel briefly summarized their written testimony and then took questions. Among the points made during this panel were the following:

  • Cook did not support the bill and criticized the preemption approach particularly. Cook criticized S. 697 for allowing chemicals to be used so long as they pose "no unreasonable risk of harm," rather than ensuring that the chemicals pose a "reasonable certainty of no harm." According to Cook, this second standard has been used successfully in evaluating pesticides, and has not resulted in banning them all.
  • Frosh, while agreeing that TSCA needed an overhaul, indicated strong concerns with the preemption provision. According to Frosh, S. 697 would put states out of the business of protecting their citizens from poison by, among other ways, prohibiting new state restrictions from the moment EPA begins consideration of high priority chemicals with a seven-year timeline before regulation is required, and no state can take action in the interim regardless of how toxic the chemical is. Frosh stated that priority is upside down -- if a chemical is dangerous, EPA should be required to act as quickly as possible.
  • Goldman, former EPA Assistant Administrator for Prevention, Pesticides, and Toxic Substances, recounted her experience of testifying in support of TSCA change in the 1990s and supported S. 697 as dealing with many of the issues presented by TSCA even though the bill could be improved. She noted that S. 697 provides EPA with strong authority to require testing; deletes "least burdensome requirement" in taking Section 6 action; and has CBI provisions that would open up vast quantities of information that never should have been confidential or are outdated and would allow sharing CBI with states. The deadlines under S. 697 include fees that would be used to support EPA in its chemicals work. Goldman noted that S. 697 does not freeze the science by injecting 2015 science into a law that will need to work for a number of years. California's Proposition 65 and certain other state efforts would not be preempted; rather, S. 697 would allow EPA to protect all citizens, not just residents of certain states that take action. Regarding the issue of new chemicals, an area which no one else had raised, she stated that the bill was a strong improvement over TSCA. In an interesting exchange with Senator Barbara Boxer (D-CA), Goldman agreed to review and offer a response to the letters submitted by legal experts who had argued that the bill was worse than current law.
  • McCabe testified that S. 697 is a critical step towards a bill that will be protective of maternal and children's health, and that the bill represented a starting point.
  • Denison testified that he and his organization, Environmental Defense Fund, support S. 697 as it fixes the biggest problems in TSCA, has strong bipartisan support, and represents a culmination of a decade of work by Senator Lautenberg, all while acknowledging that the bill is less than he would want. Denison agreed that preemption had proven to be an exceedingly difficult issue, and that S. 697 is more preemptive than current law, but less so than the original bill. He also noted that while he strongly supported their efforts, state actions have restricted only about a dozen chemicals or classes of chemicals and that it was clear that a broad and effective federal effort such as in S. 697 was needed.


Notwithstanding the detailed opinions expressed by Senators and witnesses, the hearing went according to a mostly predictable pace and script. Senators Boxer and Ed Markey (D-MA), opposed to S. 697, cited what they described as fatal flaws in the legislation and the "overwhelming" correspondence received in opposition to the bill by environmental and citizen groups and other organizations that want a strengthened bill. The main cause of concern is rooted in the preemption provisions of the proposal, where passionate arguments about the wisdom, strength, courage, leadership, skills, and intuition of state governments were touted to indicate that any restriction on state actions would be catastrophic to the proper control of chemical exposures. Senator Boxer-supportive witnesses were asked to verify the concerns. In support of the legislation, Senator Vitter went through the various catalogs of principles, e.g., by the Obama Administration, to highlight how S. 697 addresses those concerns and asked witnesses to affirm that such principles did indeed capture the spirit and intent of the principles. In the end, as was known beforehand, the most difficult issue remains how or whether to fashion preemption boundaries on state actions.

Unfortunately, the soaring rhetoric praising states' rights mostly blurred the substantive issues of how and where to draw any lines restricting any state actions. Almost in passing was mentioned how the universe of current state action about chemicals affects only approximately twelve chemicals -- which is a sufficiently low number to support both pro and con positions (what is the big deal, only twelve times has it happened; twelve is just the start of what could be a large number of state-regulated chemicals).

Through the rhetorical fog, some key issues that are ripe for further development emerged, such as the need to consider whether TSCA's preemptive effect should begin when any federal restrictions are imposed, during the time EPA considers "high-priority" chemicals, or at other times. The inherent possibility for long delays in completing reviews of difficult, scientifically complex assessments, and wanting to create new incentives for delays, was a recurring theme and suggests among the panel members that more tinkering can be expected. Making any preemptive effect begin at the conclusion of an EPA assessment will create incentives for chemical producers to assist with completion of the task. This option seemed to interest Committee members who spoke of trying to find further improvements.

There was also much mention made of the need for states to have independent authority to enforce actions EPA may take, as is the case in other environmental laws. At the end of the day, the tone of the panel was that this might be another area of further compromise.

In our view, it is clear from the hearing that the following areas in S. 697 need attention:

  • Preemption, which is no surprise, although there were some interesting suggestions offered, such as some variant on the approach to preemption in Dodd-Frank or in FIFRA. At the same time, the point was made that the bill deals with products and thus the approach should perhaps follow that in the Federal Food, Drug, and Cosmetic Act (FFDCA) regarding federal drug preemption.
  • Article provisions that are scattered in the bill need to be clarified and improved as they present technical issues challenges for EPA as currently structured. There are also concerns about the scope of the requirement on EPA to review each type of article and what this would mean for delaying or complicating EPA action, as well as the approach in Section 13 regarding import certifications for articles.
  • Deadlines and targets for assessment and control action (particularly a deadline for when a regulation must take effect) need to be revisited, although EPA indicated that the maximum number of regulatory review actions it could handle is about 40 per year (Jones based his estimate on his experience in the pesticide program).
  • Final agency action/judicial review must be available for low priority designations made by EPA.
  • One witness (Goldman) raised the need to address treaty issues presented by the Stockholm Convention on Persistent Organic Pollutants (POPs) and Rotterdam Convention on Prior Informed Consent (PIC).

A surprisingly large portion of the bill did not come up as an issue:

  • CBI received relatively little treatment, which may be due to its complexity and lack of expertise on the issue among witnesses.
  • No issues were raised about the approach to Section 4 testing.
  • The requirements on and deadlines for EPA to develop policies, procedures, and guidance in Section 4A were not raised as an issue and Jones indicated that he thought EPA could do what was required.
  • Goldman was the only witness to raise Section 5 new chemicals issues and no one disagreed with her statement that S. 697 improved on TSCA.
  • The prioritization screening approach, other than numbers and final agency action issue, did not elicit concerns.
  • None of the witnesses raised issues with the approaches in Section 8, including the active versus inactive chemicals list.
  • Judicial review had a passing question.
  • The fees approach was not challenged other than issues with industry paying for reviews, although we suspect that issues are lurking.

So now what? Does the legislation stand a chance of enactment even with over "hundreds of organizations" claiming that S. 697 is worse than current law (this is the number Senator Boxer cited as her count). The short answer is yes. The legislation already has eight Democrats as co-sponsors, which, if combined with the 54 Republican members, would be a working majority (over the needed 60-vote threshold to overcome a filibuster). It appears too soon to expect serious hardball in terms of vote-counting and floor action, and some of the noises coming from the hearing were bridges of opportunity to address some of the major issues identified (including deadlines, pace of EPA progress, budget, final agency action status of low priority designations, fees, imports, and regulation of articles to name a few). Preemption was and is the remaining obstacle, but at the end of the day, that could come down to vote counting. If there are 61 votes on the Senate floor, and the House action does not further complicate matters (not to mention a need for the President to sign the bill), TSCA reform could happen.

Among the most compelling testimony was Dr. Goldman's reminder to the Committee that she first testified about the need for TSCA amendments in 1994 as Assistant Administrator -- over 20 years ago. In a question and answer with Senator Vitter, Jones indicated that since 1990 with the current law, almost no chemicals have been banned or tested (one might quibble with the wording about the numbers tested or restricted, but Jones' answers made the point). Also testifying was Senator Lautenberg's widow, who stated that the late Senator believed TSCA reform would be perhaps the most singular achievement of his long Senate career -- more important than his signature achievement of banning smoking on airplanes years ago.

The dueling themes of "don't let the perfect be the enemy of the good" vs. "this bill is worse than current law" will need to be sufficiently brought together even if consensus is too far a goal. The specter of living with the current law for another 20-40 years is unpalatable to many interested stakeholders of different perspectives (a point made by Goldman). In the end, the summary slogan of any successful legislation may be "better than the alternative" -- but stranger things have happened and even that would not have been expected last November when the Senate majority flipped to Republican control.

[View source.]

Written by:

Bergeson & Campbell, P.C.

Bergeson & Campbell, P.C. on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide

JD Supra Privacy Policy

Updated: May 25, 2018:

JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.

This Privacy Policy describes how JD Supra, LLC ("JD Supra" or "we," "us," or "our") collects, uses and shares personal data collected from visitors to our website (located at www.jdsupra.com) (our "Website") who view only publicly-available content as well as subscribers to our services (such as our email digests or author tools)(our "Services"). By using our Website and registering for one of our Services, you are agreeing to the terms of this Privacy Policy.

Please note that if you subscribe to one of our Services, you can make choices about how we collect, use and share your information through our Privacy Center under the "My Account" dashboard (available if you are logged into your JD Supra account).

Collection of Information

Registration Information. When you register with JD Supra for our Website and Services, either as an author or as a subscriber, you will be asked to provide identifying information to create your JD Supra account ("Registration Data"), such as your:

  • Email
  • First Name
  • Last Name
  • Company Name
  • Company Industry
  • Title
  • Country

Other Information: We also collect other information you may voluntarily provide. This may include content you provide for publication. We may also receive your communications with others through our Website and Services (such as contacting an author through our Website) or communications directly with us (such as through email, feedback or other forms or social media). If you are a subscribed user, we will also collect your user preferences, such as the types of articles you would like to read.

Information from third parties (such as, from your employer or LinkedIn): We may also receive information about you from third party sources. For example, your employer may provide your information to us, such as in connection with an article submitted by your employer for publication. If you choose to use LinkedIn to subscribe to our Website and Services, we also collect information related to your LinkedIn account and profile.

Your interactions with our Website and Services: As is true of most websites, we gather certain information automatically. This information includes IP addresses, browser type, Internet service provider (ISP), referring/exit pages, operating system, date/time stamp and clickstream data. We use this information to analyze trends, to administer the Website and our Services, to improve the content and performance of our Website and Services, and to track users' movements around the site. We may also link this automatically-collected data to personal information, for example, to inform authors about who has read their articles. Some of this data is collected through information sent by your web browser. We also use cookies and other tracking technologies to collect this information. To learn more about cookies and other tracking technologies that JD Supra may use on our Website and Services please see our "Cookies Guide" page.

How do we use this information?

We use the information and data we collect principally in order to provide our Website and Services. More specifically, we may use your personal information to:

  • Operate our Website and Services and publish content;
  • Distribute content to you in accordance with your preferences as well as to provide other notifications to you (for example, updates about our policies and terms);
  • Measure readership and usage of the Website and Services;
  • Communicate with you regarding your questions and requests;
  • Authenticate users and to provide for the safety and security of our Website and Services;
  • Conduct research and similar activities to improve our Website and Services; and
  • Comply with our legal and regulatory responsibilities and to enforce our rights.

How is your information shared?

  • Content and other public information (such as an author profile) is shared on our Website and Services, including via email digests and social media feeds, and is accessible to the general public.
  • If you choose to use our Website and Services to communicate directly with a company or individual, such communication may be shared accordingly.
  • Readership information is provided to publishing law firms and authors of content to give them insight into their readership and to help them to improve their content.
  • Our Website may offer you the opportunity to share information through our Website, such as through Facebook's "Like" or Twitter's "Tweet" button. We offer this functionality to help generate interest in our Website and content and to permit you to recommend content to your contacts. You should be aware that sharing through such functionality may result in information being collected by the applicable social media network and possibly being made publicly available (for example, through a search engine). Any such information collection would be subject to such third party social media network's privacy policy.
  • Your information may also be shared to parties who support our business, such as professional advisors as well as web-hosting providers, analytics providers and other information technology providers.
  • Any court, governmental authority, law enforcement agency or other third party where we believe disclosure is necessary to comply with a legal or regulatory obligation, or otherwise to protect our rights, the rights of any third party or individuals' personal safety, or to detect, prevent, or otherwise address fraud, security or safety issues.
  • To our affiliated entities and in connection with the sale, assignment or other transfer of our company or our business.

How We Protect Your Information

JD Supra takes reasonable and appropriate precautions to insure that user information is protected from loss, misuse and unauthorized access, disclosure, alteration and destruction. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. You should keep in mind that no Internet transmission is ever 100% secure or error-free. Where you use log-in credentials (usernames, passwords) on our Website, please remember that it is your responsibility to safeguard them. If you believe that your log-in credentials have been compromised, please contact us at privacy@jdsupra.com.

Children's Information

Our Website and Services are not directed at children under the age of 16 and we do not knowingly collect personal information from children under the age of 16 through our Website and/or Services. If you have reason to believe that a child under the age of 16 has provided personal information to us, please contact us, and we will endeavor to delete that information from our databases.

Links to Other Websites

Our Website and Services may contain links to other websites. The operators of such other websites may collect information about you, including through cookies or other technologies. If you are using our Website or Services and click a link to another site, you will leave our Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We are not responsible for the data collection and use practices of such other sites. This Policy applies solely to the information collected in connection with your use of our Website and Services and does not apply to any practices conducted offline or in connection with any other websites.

Information for EU and Swiss Residents

JD Supra's principal place of business is in the United States. By subscribing to our website, you expressly consent to your information being processed in the United States.

  • Our Legal Basis for Processing: Generally, we rely on our legitimate interests in order to process your personal information. For example, we rely on this legal ground if we use your personal information to manage your Registration Data and administer our relationship with you; to deliver our Website and Services; understand and improve our Website and Services; report reader analytics to our authors; to personalize your experience on our Website and Services; and where necessary to protect or defend our or another's rights or property, or to detect, prevent, or otherwise address fraud, security, safety or privacy issues. Please see Article 6(1)(f) of the E.U. General Data Protection Regulation ("GDPR") In addition, there may be other situations where other grounds for processing may exist, such as where processing is a result of legal requirements (GDPR Article 6(1)(c)) or for reasons of public interest (GDPR Article 6(1)(e)). Please see the "Your Rights" section of this Privacy Policy immediately below for more information about how you may request that we limit or refrain from processing your personal information.
  • Your Rights
    • Right of Access/Portability: You can ask to review details about the information we hold about you and how that information has been used and disclosed. Note that we may request to verify your identification before fulfilling your request. You can also request that your personal information is provided to you in a commonly used electronic format so that you can share it with other organizations.
    • Right to Correct Information: You may ask that we make corrections to any information we hold, if you believe such correction to be necessary.
    • Right to Restrict Our Processing or Erasure of Information: You also have the right in certain circumstances to ask us to restrict processing of your personal information or to erase your personal information. Where you have consented to our use of your personal information, you can withdraw your consent at any time.

You can make a request to exercise any of these rights by emailing us at privacy@jdsupra.com or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

You can also manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard.

We will make all practical efforts to respect your wishes. There may be times, however, where we are not able to fulfill your request, for example, if applicable law prohibits our compliance. Please note that JD Supra does not use "automatic decision making" or "profiling" as those terms are defined in the GDPR.

  • Timeframe for retaining your personal information: We will retain your personal information in a form that identifies you only for as long as it serves the purpose(s) for which it was initially collected as stated in this Privacy Policy, or subsequently authorized. We may continue processing your personal information for longer periods, but only for the time and to the extent such processing reasonably serves the purposes of archiving in the public interest, journalism, literature and art, scientific or historical research and statistical analysis, and subject to the protection of this Privacy Policy. For example, if you are an author, your personal information may continue to be published in connection with your article indefinitely. When we have no ongoing legitimate business need to process your personal information, we will either delete or anonymize it, or, if this is not possible (for example, because your personal information has been stored in backup archives), then we will securely store your personal information and isolate it from any further processing until deletion is possible.
  • Onward Transfer to Third Parties: As noted in the "How We Share Your Data" Section above, JD Supra may share your information with third parties. When JD Supra discloses your personal information to third parties, we have ensured that such third parties have either certified under the EU-U.S. or Swiss Privacy Shield Framework and will process all personal data received from EU member states/Switzerland in reliance on the applicable Privacy Shield Framework or that they have been subjected to strict contractual provisions in their contract with us to guarantee an adequate level of data protection for your data.

California Privacy Rights

Pursuant to Section 1798.83 of the California Civil Code, our customers who are California residents have the right to request certain information regarding our disclosure of personal information to third parties for their direct marketing purposes.

You can make a request for this information by emailing us at privacy@jdsupra.com or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

Some browsers have incorporated a Do Not Track (DNT) feature. These features, when turned on, send a signal that you prefer that the website you are visiting not collect and use data regarding your online searching and browsing activities. As there is not yet a common understanding on how to interpret the DNT signal, we currently do not respond to DNT signals on our site.

Access/Correct/Update/Delete Personal Information

For non-EU/Swiss residents, if you would like to know what personal information we have about you, you can send an e-mail to privacy@jdsupra.com. We will be in contact with you (by mail or otherwise) to verify your identity and provide you the information you request. We will respond within 30 days to your request for access to your personal information. In some cases, we may not be able to remove your personal information, in which case we will let you know if we are unable to do so and why. If you would like to correct or update your personal information, you can manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard. If you would like to delete your account or remove your information from our Website and Services, send an e-mail to privacy@jdsupra.com.

Changes in Our Privacy Policy

We reserve the right to change this Privacy Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our Privacy Policy will become effective upon posting of the revised policy on the Website. By continuing to use our Website and Services following such changes, you will be deemed to have agreed to such changes.

Contacting JD Supra

If you have any questions about this Privacy Policy, the practices of this site, your dealings with our Website or Services, or if you would like to change any of the information you have provided to us, please contact us at: privacy@jdsupra.com.

JD Supra Cookie Guide

As with many websites, JD Supra's website (located at www.jdsupra.com) (our "Website") and our services (such as our email article digests)(our "Services") use a standard technology called a "cookie" and other similar technologies (such as, pixels and web beacons), which are small data files that are transferred to your computer when you use our Website and Services. These technologies automatically identify your browser whenever you interact with our Website and Services.

How We Use Cookies and Other Tracking Technologies

We use cookies and other tracking technologies to:

  1. Improve the user experience on our Website and Services;
  2. Store the authorization token that users receive when they login to the private areas of our Website. This token is specific to a user's login session and requires a valid username and password to obtain. It is required to access the user's profile information, subscriptions, and analytics;
  3. Track anonymous site usage; and
  4. Permit connectivity with social media networks to permit content sharing.

There are different types of cookies and other technologies used our Website, notably:

  • "Session cookies" - These cookies only last as long as your online session, and disappear from your computer or device when you close your browser (like Internet Explorer, Google Chrome or Safari).
  • "Persistent cookies" - These cookies stay on your computer or device after your browser has been closed and last for a time specified in the cookie. We use persistent cookies when we need to know who you are for more than one browsing session. For example, we use them to remember your preferences for the next time you visit.
  • "Web Beacons/Pixels" - Some of our web pages and emails may also contain small electronic images known as web beacons, clear GIFs or single-pixel GIFs. These images are placed on a web page or email and typically work in conjunction with cookies to collect data. We use these images to identify our users and user behavior, such as counting the number of users who have visited a web page or acted upon one of our email digests.

JD Supra Cookies. We place our own cookies on your computer to track certain information about you while you are using our Website and Services. For example, we place a session cookie on your computer each time you visit our Website. We use these cookies to allow you to log-in to your subscriber account. In addition, through these cookies we are able to collect information about how you use the Website, including what browser you may be using, your IP address, and the URL address you came from upon visiting our Website and the URL you next visit (even if those URLs are not on our Website). We also utilize email web beacons to monitor whether our emails are being delivered and read. We also use these tools to help deliver reader analytics to our authors to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

Analytics/Performance Cookies. JD Supra also uses the following analytic tools to help us analyze the performance of our Website and Services as well as how visitors use our Website and Services:

  • HubSpot - For more information about HubSpot cookies, please visit legal.hubspot.com/privacy-policy.
  • New Relic - For more information on New Relic cookies, please visit www.newrelic.com/privacy.
  • Google Analytics - For more information on Google Analytics cookies, visit www.google.com/policies. To opt-out of being tracked by Google Analytics across all websites visit http://tools.google.com/dlpage/gaoptout. This will allow you to download and install a Google Analytics cookie-free web browser.

Facebook, Twitter and other Social Network Cookies. Our content pages allow you to share content appearing on our Website and Services to your social media accounts through the "Like," "Tweet," or similar buttons displayed on such pages. To accomplish this Service, we embed code that such third party social networks provide and that we do not control. These buttons know that you are logged in to your social network account and therefore such social networks could also know that you are viewing the JD Supra Website.

Controlling and Deleting Cookies

If you would like to change how a browser uses cookies, including blocking or deleting cookies from the JD Supra Website and Services you can do so by changing the settings in your web browser. To control cookies, most browsers allow you to either accept or reject all cookies, only accept certain types of cookies, or prompt you every time a site wishes to save a cookie. It's also easy to delete cookies that are already saved on your device by a browser.

The processes for controlling and deleting cookies vary depending on which browser you use. To find out how to do so with a particular browser, you can use your browser's "Help" function or alternatively, you can visit http://www.aboutcookies.org which explains, step-by-step, how to control and delete cookies in most browsers.

Updates to This Policy

We may update this cookie policy and our Privacy Policy from time-to-time, particularly as technology changes. You can always check this page for the latest version. We may also notify you of changes to our privacy policy by email.

Contacting JD Supra

If you have any questions about how we use cookies and other tracking technologies, please contact us at: privacy@jdsupra.com.

- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.